20 results
8-K
EX-99.2
LBPH
Longboard Pharmaceuticals, Inc.
1 Aug 24
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
4:10pm
with significant commercial opportunities Well-understood targets
Longboard’s Potentially Best-in-Class Product Candidates Program MOA Therapeutic Area …
The Potential of Bexicaserin IP protection*** up to 2041 *Radioligand binding assays assessing150 targets showed significant affinity only to 5-HT2C
8-K
EX-99.2
LBPH
Longboard Pharmaceuticals, Inc.
12 Mar 24
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
4:10pm
/ PD and target engagement CNS programs with significant commercial opportunities Well-understood targets
Longboard’s Potentially Best-in-Class … of Bexicaserin (LP352) *Radioligand binding assays assessing150 targets showed significant affinity only to 5-HT2C receptors ** Based on first two cohorts from
424B5
onthm3vvjy8 zcj84
4 Jan 24
Prospectus supplement for primary offering
4:48pm
424B5
zojp11fg53
2 Jan 24
Prospectus supplement for primary offering
4:54pm
8-K
EX-99.1
5tmd2ii63bsfo8
29 Nov 23
Regulation FD Disclosure
8:35am
424B5
q5zi 7fzyj0s
4 Aug 23
Prospectus supplement for primary offering
4:20pm
8-K
EX-99.1
qdl6ak007hcc7c isj
5 Dec 22
Regulation FD Disclosure
8:45am
S-3
hdh7ckz9w3oh
30 Sep 22
Shelf registration
4:11pm
10-K
x6peb
3 Mar 22
Annual report
4:31pm
8-K
EX-99.1
zbcxta60 roi
10 Jan 22
Regulation FD Disclosure
7:01am
424B4
8o94s95ndxfxv
12 Mar 21
Prospectus supplement with pricing info
5:02pm
S-1/A
mksuu4gu7ct
8 Mar 21
IPO registration (amended)
6:13am
S-1/A
EX-1.1
zwp wtp4m
8 Mar 21
IPO registration (amended)
6:13am
S-1/A
EX-10.4
k55f9v
8 Mar 21
IPO registration (amended)
6:13am
S-1
8w1aaeo6
19 Feb 21
IPO registration
5:30pm
DRS/A
bw9bftfsayzw
29 Jan 21
Draft registration statement (amended)
12:00am
DRS
42uiux
15 Dec 20
Draft registration statement
12:00am
- Prev
- 1
- Next